Exicure (XCUR) - Company Gross Revenue

Exicure, Inc. (XCUR) is strengthening its position among genetic developers through its authority in the field of spherical nucleic acids. The company's product sales dynamics clearly demonstrate the financial backdrop, where 0.00 indicates the level of this metric. The future of the business relies on the success of its restructuring and the search for investors. Currently, Exicure, Inc. (XCUR) is in a stage of stagnation, seeking to minimize administrative expenses following the closure of legacy R&D directions.

exicuretx.com - XCUR Revenue and Sales Volume (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for Exicure (XCUR)

- share price and expert price forecast:

Price Performance Chart Exicure, Inc.|XCUR - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Exicure Corp|XCUR - Total Company Value

- book capitalization data:

Equity per Share Exicure|XCUR - Book Capitalization|Market Cap to Net Assets Ratio exicuretx.com|XCUR - Cumulative Company Assets

- company liabilities and liquidity data:

- financial results and valuation multiples details:

XCUR - Net Profit|Net Profit Forecast Exicure, Inc.|XCUR - Price to Earnings Ratio|Price to Future Earnings Ratio Exicure, Inc.|XCUR - PEG Multiple|EV/EBITDA Multiple Exicure Inc.|XCUR - Operating profit EBITDA|Net earnings per one share for the last twelve months Exicure|XCUR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months exicuretx.com|XCUR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Exicure, Inc.

- company sales and revenue statistics:

XCUR - Revenue and Sales Volume|Company Future Sales Volume Exicure|XCUR - Market Cap to Revenue|Forward P/S Multiple Exicure Corp|XCUR - Sales Growth YoY (Last Twelve Months)

Summary company analysis:XCUR Exicure Corp

Sales reflect the total volume of cash inflows from product realization, serving as a key indicator of the business's operational viability. Analyzing the company's overall sales level allows for an assessment of revenue recovery rates and actual market demand. This metric measures the nominal inflow of funds, confirming the issuer's ability to monetize its developments. For Exicure, Inc. (XCUR), this indicator demonstrates the commercial efficiency of implementing the SNA platform into precision skin and lung therapy.

Competing companies